Biogen Inc. (NASDAQ:BIIB) Shares Bought by Bank Julius Baer & Co. Ltd Zurich

Bank Julius Baer & Co. Ltd Zurich raised its position in Biogen Inc. (NASDAQ:BIIB) by 3.2% during the 4th quarter, Holdings Channel.com reports. The firm owned 1,712 shares of the biotechnology company’s stock after acquiring an additional 53 shares during the quarter. Bank Julius Baer & Co. Ltd Zurich’s holdings in Biogen were worth $443,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in BIIB. OFI Invest Asset Management acquired a new stake in shares of Biogen in the third quarter valued at approximately $26,000. Gladius Capital Management LP acquired a new position in shares of Biogen during the third quarter valued at approximately $28,000. KB Financial Partners LLC increased its stake in shares of Biogen by 105.1% during the third quarter. KB Financial Partners LLC now owns 121 shares of the biotechnology company’s stock valued at $31,000 after acquiring an additional 62 shares during the period. CVA Family Office LLC acquired a new position in shares of Biogen during the fourth quarter valued at approximately $36,000. Finally, Baker Avenue Asset Management LP increased its stake in shares of Biogen by 215.5% during the third quarter. Baker Avenue Asset Management LP now owns 183 shares of the biotechnology company’s stock valued at $47,000 after acquiring an additional 125 shares during the period. Institutional investors and hedge funds own 87.93% of the company’s stock.

Biogen Stock Up 3.2 %

Biogen stock opened at $208.90 on Friday. The company has a market capitalization of $30.42 billion, a P/E ratio of 26.08, a P/E/G ratio of 2.13 and a beta of -0.02. The firm’s fifty day simple moving average is $212.55 and its 200-day simple moving average is $233.57. The company has a current ratio of 2.10, a quick ratio of 1.26 and a debt-to-equity ratio of 0.41. Biogen Inc. has a 1-year low of $189.44 and a 1-year high of $319.76.

Biogen (NASDAQ:BIIB) last released its quarterly earnings results on Wednesday, April 24th. The biotechnology company reported $3.67 earnings per share for the quarter, beating analysts’ consensus estimates of $3.45 by $0.22. The business had revenue of $2.29 billion for the quarter, compared to the consensus estimate of $2.31 billion. Biogen had a net margin of 12.07% and a return on equity of 14.83%. Biogen’s revenue for the quarter was down 7.0% on a year-over-year basis. During the same quarter last year, the firm earned $3.40 EPS. Sell-side analysts forecast that Biogen Inc. will post 15.57 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Priya Singhal sold 262 shares of Biogen stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $221.23, for a total value of $57,962.26. Following the transaction, the insider now owns 4,886 shares in the company, valued at approximately $1,080,929.78. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, Director Eric K. Rowinsky bought 455 shares of the company’s stock in a transaction that occurred on Thursday, February 15th. The shares were purchased at an average price of $222.54 per share, for a total transaction of $101,255.70. Following the acquisition, the director now directly owns 20,629 shares of the company’s stock, valued at approximately $4,590,777.66. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Priya Singhal sold 262 shares of Biogen stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $221.23, for a total transaction of $57,962.26. Following the completion of the transaction, the insider now owns 4,886 shares in the company, valued at approximately $1,080,929.78. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 882 shares of company stock worth $202,030. 0.60% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on BIIB shares. Bank Of America (Bofa) lowered their price objective on shares of Biogen from $290.00 to $280.00 and set a “neutral” rating on the stock in a research note on Monday, February 12th. JPMorgan Chase & Co. lowered their price objective on shares of Biogen from $270.00 to $240.00 and set a “neutral” rating on the stock in a research note on Thursday, April 11th. William Blair reiterated an “outperform” rating on shares of Biogen in a research note on Monday, April 1st. BTIG Research restated a “neutral” rating on shares of Biogen in a research report on Sunday, January 7th. Finally, Wedbush lifted their price target on shares of Biogen from $213.00 to $215.00 and gave the stock a “neutral” rating in a research report on Thursday. Ten research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $293.88.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.